Skip to main content
SpringerLink
Log in

Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Evans R, Barish G, Wang YX: PPARS and the complex journey to obesity. Nat Med 2004, 10:1–7.

    Article  CAS  Google Scholar 

  2. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR{alpha} in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571–580.

    Article  PubMed  CAS  Google Scholar 

  3. Semple RK, Chatterjee VK, O’Rahilly S: PPAR{gamma} and human metabolic disease. J Clin Invest 2006, 116:581–589.

    Article  PubMed  CAS  Google Scholar 

  4. Barish GD, Narkar VA, Evans RM: PPAR{delta}: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590–597.

    Article  PubMed  CAS  Google Scholar 

  5. Wang YX: Peroxisome-proliferator-activated receptor delta activated fat metabolism to prevent obesity. Cell 2003, 113:159–170.

    Article  PubMed  CAS  Google Scholar 

  6. Howard BV, Rodriguez BL, Bennett PH, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology. Circulation 2002, 105:132e-137.

    Article  Google Scholar 

  7. Grundy SM: Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997, 95:1–4.

    PubMed  CAS  Google Scholar 

  8. Dormandy J, Charbonnel B, Eckland D, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  9. Robinson JG, Smith B, Maheshwari N, Schrott H: “Pleiotropic” effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.

    Article  PubMed  CAS  Google Scholar 

  10. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585–1591.

    Article  PubMed  CAS  Google Scholar 

  11. Jones PH, Davidson MH, Stein EA, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152–160.

    Article  PubMed  CAS  Google Scholar 

  12. Rubins H, Robins S, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  13. Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360–380.

    Article  Google Scholar 

  14. Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978, 40:1069–1118.

    Article  Google Scholar 

  15. Frick M, Heinonen O, Huttenen J, et al.: Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 1993, 25:41–45.

    PubMed  CAS  Google Scholar 

  16. Heinonen O, Huttunen J, Manninen V, et al.: The Helsinki Heart Study: Coronary heart disease incidence during an extended follow-up. J Intern Med 1994, 235:41–49.

    Article  PubMed  CAS  Google Scholar 

  17. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21–27.

    Google Scholar 

  18. Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  CAS  Google Scholar 

  19. Luc G, Jacob N, Bouly M, et al.: Fenofibrate increases homocystinemia through a PPAR-alpha-mediated mechanism. J Cardiovasc Pharmacol 2004, 43:452–453.

    Article  PubMed  CAS  Google Scholar 

  20. Mayer O, Åimon J, Holubec L, et al.: Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol 2003, 59:367–371.

    Article  PubMed  Google Scholar 

  21. The Heart Outcomes Prevention Evaluation I. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567–1577.

    Google Scholar 

  22. Westphal S, Dierkes J, Luley C: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001, 358:39–40.

    Article  PubMed  CAS  Google Scholar 

  23. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002, 162:2597–2604.

    Article  PubMed  CAS  Google Scholar 

  24. DAIS Study Group: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905–910.

    Article  Google Scholar 

  25. National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.

    Google Scholar 

  26. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Article  CAS  Google Scholar 

  27. Calhoun H, Betteridge D, Durrington P, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  CAS  Google Scholar 

  28. Shepherd J, Barter P, Carmena R, et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220–1226.

    Article  PubMed  CAS  Google Scholar 

  29. ACCORD purpose; June 30, 2006. http://www.accordtrial.org. Accessed July 12, 2006.

  30. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005, 95:120–122.

    Article  PubMed  CAS  Google Scholar 

  31. Robinson JG, Stone N: Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids Am J Cardiol 2006, 98(4 Suppl 1):39i-49i.

    Article  PubMed  CAS  Google Scholar 

  32. Wang C, Harris WS, Chung M, et al.: n-3 Fatty acids from fish or fish-oil supplements, but not {alpha}-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006 84:5–17.

    PubMed  CAS  Google Scholar 

  33. Dormandy J, Charbonnel B, Eckland D, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PRO spective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  34. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941–2948.

    Article  PubMed  Google Scholar 

  35. Selvin E, Marinopoulos S, Berkenblit G, et al.: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421–431.

    PubMed  CAS  Google Scholar 

  36. Gotto AM Jr, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004, 43:717–724.

    Article  PubMed  CAS  Google Scholar 

  37. Goldberg RB, Kendall DM, Deeg MA, et al.: A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.

    Article  PubMed  CAS  Google Scholar 

  38. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003, 9:1–9.

    PubMed  CAS  Google Scholar 

  39. Takeda Pharmaceuticals. Actos [piogltiazone hydrochloride] prescribing information. http://www.actos.com/sub_sec1_what_actos.asp. Accessed July 13, 2006.

  40. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963–1972.

    Article  PubMed  Google Scholar 

  41. Viberti G, Kahn SE, Greene DA, et al.: A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25:1737–1743.

    Article  PubMed  CAS  Google Scholar 

  42. The Dream Trial Investigators: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519–1527.

    Article  CAS  Google Scholar 

  43. Abraira C, Duckworth W, McCarren M, et al.: Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003, 17:314–322.

    Article  PubMed  Google Scholar 

  44. Brooks MM, Frye RL, Genuth S, et al.: Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006, 97(Suppl 1):9–19.

    Article  Google Scholar 

  45. Home P, Pocock S, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726–1735.

    Article  PubMed  CAS  Google Scholar 

  46. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581–2586.

    Article  PubMed  CAS  Google Scholar 

  47. Kendall DM, Rubin CJ, Mohideen P, et al.: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual ({alpha}/{gamma}) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006, 29:1016–1023.

    Article  PubMed  CAS  Google Scholar 

  48. Tenenbaum A, Motro M, Fisman E: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetology 2005, 4:14.

    Article  CAS  Google Scholar 

  49. The Diabetes Prevention Program Research Group: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54:1150–1156.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid Research Clinic, Departments of Epidemiology & Medicine, University of Iowa, 200 Hawkins Drive SE, 226 GH, 52242, Iowa City, IA, USA

    Jennifer G. Robinson MD, MPH

Authors
  1. Jennifer G. Robinson MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer G. Robinson MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, J.G. Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE. Curr Atheroscler Rep 9, 64–71 (2007). https://doi.org/10.1007/BF02693930

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02693930

Keywords

Search

Navigation